Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$113.64 USD

113.64
6,318,358

+0.55 (0.49%)

Updated Sep 27, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Growth in New Drugs to Give a Boost to Roche (RHHBY) Q1 Sales

by Zacks Equity Research

Roche's (RHHBY) newer drugs are likely to have combated the biosimilar competition for legacy drugs in the first quarter.

Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre

by Zacks Equity Research

Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.

Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts

by Kinjel Shah

J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines

Merck (MRK) Stock Moves -0.93%: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $82.07, moving -0.93% from the previous trading session.

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2020. It lowers its adjusted earnings and sales outlook for 2020 for coronavirus-related uncertainty. Stock up.

AstraZeneca's Koselugo Gets FDA Nod for Rare Genetic Disorder

by Zacks Equity Research

The FDA approves AstraZeneca (AZN) and Merck's kinase inhibitor, Koselugo, for treating pediatric patients with neurofibromatosis type 1 (NF1) having symptomatic, inoperable plexiform neurofibromas.

Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?

by Zacks Equity Research

J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.

Merck (MRK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $82.46, moving +1.03% from the previous trading session.

J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.

    Bristol Myers' Applications for Opdivo-Yervoy Combo Accepted

    by Zacks Equity Research

    Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.

    Merck's Keytruda Gets FDA's Priority Review for Solid Tumors

    by Zacks Equity Research

    Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.

    Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC

    by Zacks Equity Research

    The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).

    Kinjel Shah headshot

    Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market

    by Kinjel Shah

    The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.

    Esperion's Cholesterol Drugs Receive Approval in Europe

    by Zacks Equity Research

    Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.

    Immunomedics Up as Breast Cancer Drug Study Shows Efficacy

    by Zacks Equity Research

    Immunomedics (IMMU) soars as the phase III study on breast cancer drug shows efficacy and will be subsequently halted.

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM

    Benjamin Rains headshot

    3 Stocks Immune to the Coronavirus Downturn to Buy Right Now

    by Benjamin Rains

    Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...

    The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck

    Sheraz Mian headshot

    Top Stock Reports for J&J, Merck, Novartis & Others

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Merck (MRK) and Novartis (NVS).

    Merck (MRK) Stock Moves -0.81%: What You Should Know

    by Zacks Equity Research

    Merck (MRK) closed at $76.25 in the latest trading session, marking a -0.81% move from the prior day.

    Why Merck (MRK) is Poised to Beat Earnings Estimates Again

    by Zacks Equity Research

    Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    Seattle Genetics Issue Update on Padcev Label Expansion Study

    by Zacks Equity Research

    Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.

    Kinjel Shah headshot

    Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates

    by Kinjel Shah

    J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.